




**Figure S1.** MDM2i abrogates formation of DNA damage foci in AURKAI-treated cells. Imaging flow cytometry analysis of Hs294T cells treated with 10 $\mu$ M Nutlin-3a (MDM2i)  $\pm$  1 $\mu$ M alisertib (AURKAI) for 3 days. **(a)** Representative images of cells. Ch01 – bright field, Ch02 –  $\gamma$ H2AX, Ch04 – DNA. **(b)** Histogram shows the percentages of cells with indicated counts of foci per cell. **(c)** Statistical analysis based on 3 independent experiments. ANOVA test was used on average foci/per cell values that were log transformed and blocked for inter-experimental variability.



**Figure S2.** Induction of polyploidy by various inhibitors of mitotic kinases. (a) SK-Mel5 cells were treated with 1 $\mu$ M alisertib (AURKAi) for 0h, 24h, or 48h and DNA content was analyzed by flow cytometry. (b) Flow cytometric analysis of DNA content in SK-Mel5 cells after 3 days of treatment with 1 $\mu$ M alisertib (AURKAi), 5 $\mu$ M danusertib (AURKA/Bi) or 5nM volasertib (PLKi).



**Figure S3.** AURKAI-induced DNA damage is not associated with nucleotide depletion or interference with transcription. **(a)** SK-Mel5 cells were treated with vehicle or 1 $\mu$ M alisertib (AURKAI) for 2 days with and without supplementation of culture media with 250 nM of mixed dNTPs: adenosine, guanosine, thymidine, and cytosine. **(b)** SK-Mel5 cells were treated with vehicle or 1 $\mu$ M alisertib (AURKAI) for 2 days and then cultured 100 minutes with or without RNA transcription inhibitor cordycepin (50  $\mu$ M).



**Figure S4.** p21 knockout sensitizes cells to MDM2i and AURKAI treatment. **(a)** Isogenic HCT116 cells with or without *CDKN1A* gene (p21) knockout were treated with 10μM Nutlin-3a (MDM2i) ± 1μM alisertib (AURKAI) for 3 days and pulsed with BRDU for 2 hours. Representative histograms of flow cytometric analysis of BRDU, γH2AX and cleaved PARP. Ten thousand events were collected for each sample. **(b)** Wild type HCT116 cells (WT) and isogenic p21 knockout cells (KO) were treated with 5 μM cisplatin (Cispl.), 100 μM temozolomide (TMZ), or 20nM volasertib (PLKi) ± 10 μM nutlin-3a (MDM2i) for 2 days. Levels of γH2AX were analyzed by western blot. Results are representative of two experiments.